A Stable mRNA-Based Novel Multi-Epitope Vaccine Designs Against Infectious Heartland Virus by Integrated Immunoinformatics and Reverse Vaccinology Approaches

Viral Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

The Heartland virus (HRTV) is a tick-borne human pathogenic phlebovirus that primarily causes leukopenia and thrombocytopenia. It transmitted by Amblyomma americanum type of tick, is, notable for their aggressive biting behavior, affinity hosts, high prevalence. Developing vaccines or immunizations against HRTV gaining importance as public-health preventive strategy. current study was planned to prioritize multi-epitope stable mRNA vaccine model from lead B-cell T-cell epitopes (with IC50 < 100 nM) proteome following advanced immunoinformatics approaches. Model constructs were designed linking the most potent, nonallergenic along with incorporation ribosomal protein adjuvant immune response enhancement. immunogenic potential coding molecule examined via molecular docking toll-like receptors followed normal mode analysis dynamics simulations-based energy minimization, stability, flexibility assessments. A robust, circular precursor multi-epitopes incorporating Kozak consensus sequence, start codon, essential elements such MHC class I trafficking domain (MITD), tPA, Goblin 5′ 3′ Untranslated Region (UTRs), poly (A) tail. This strategic amalgamation ensures elevated immunogenicity predicts promising HRTV. simulation predicted capable elicit cell-mediated humoral responses. examine experimentally its safety features.

Language: Английский

WHO report signals tuberculosis resurgence: Addressing systemic failures and revamping control strategies

Decoding Infection and Transmission, Journal Year: 2025, Volume and Issue: 3, P. 100044 - 100044

Published: Jan. 1, 2025

Language: Английский

Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2

Journal of Genetic Engineering and Biotechnology, Journal Year: 2024, Volume and Issue: 22(4), P. 100439 - 100439

Published: Nov. 16, 2024

The coronavirus that causes serious acute respiratory syndrome. Severe syndrome 2 (SARS-CoV-2) is still a major problem in public health and biomedicine. Even if there no cure for it, the infection progressing naturally, only time optimal treatment choices, such as doxycycline, work at beginning of infection. Our project structured into two critical parts: first focuses on identification potential drug targets, second vaccine design, both aimed exploring new ways to treat disease. Initially, cytoplasmic proteins identified through subtractive analysis underwent comprehensive evaluation targeting, focusing metabolic pathways, homology prediction, drugability assessment, essentiality, protein-protein interactions. Subsequently, surface rigorous assessment allergenicity, antigenicity, physiochemical attributes, conserved regions, protein interactions, B T cell epitopes. Molecular docking immunological simulation analyses were then employed develop characterize multi-epitope vaccine, integrating findings from aforementioned evaluations. Findings study point six therapeutic targets SARS-CoV-2, each which involved distinct process. reverse vaccinology suggested following could be used candidates: sp|P05106, sp|O00187, sp|Q9NYK1, sp|P05556, sp|P09958, sp|Q9HC29. Four named SARS-COV-2-, C1, C2, C3, C4 was designed by utilizing different adjuvants eighteen overlapped epitopes predicted top ranked protiens. Based immune study, exhibited adequate immune-reactivity favorable encounters with toll-type receptors (TLR4, TLR8, HLA, etc ACE), Among them SARS-COV-2-C2 showed best binding affinity all receptors. this game-changer quest medication effectively combat SARS-CoV-2. It necessary do additional experimental analyses, nevertheless.

Language: Английский